Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and...
Boehringer Ingelheim announced today the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized...
Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was...
Boehringer Ingelheim announced today new data from the pivotal Phase II Effisayil™ 1 trial, presented at the 2022 American Academy of Dermatology...
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel...
Boehringer Ingelheim announced today the publication in The New England Journal of Medicine of new data from the pivotal Phase II Effisayil™ 1 trial, ...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted...
Boehringer Ingelheim today announced that the first patient has enrolled in a new clinical study to observe whether COVID-19 patients with...
Boehringer Ingelheim today announced results from an analysis of the SENSCIS®-ON trial. SENSCIS-ON is an open-label extension trial of the Phase III...
New York Yankees legend and Latin Grammy-nominee Bernie Williams has teamed up with award-winning actress, musician and TV producer Queen Latifah,...
The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to...
Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating Ofev® (nintedanib) in patients with...
Boehringer Ingelheim today announced that Lars Dreesmann, PhD, has been named President of the company's US biopharmaceutical development and...
Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety...
Boehringer Ingelheim today announced new analyses of the Phase III INBUILD® trial that studied Ofev® (nintedanib) for the treatment of chronic...
As part of Boehringer Ingelheim's commitment to fighting the COVID-19 pandemic and long-standing partnership with the pulmonology community, the...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev® (nintedanib) as the first treatment for people...
Boehringer Ingelheim presented results from a new subgroup analyses that support the primary endpoint results from the Phase III INBUILD® trial that...
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Ofev® (nintedanib), ...
Boehringer Ingelheim announced today that in the Phase III INBUILD® trial Ofev® (nintedanib) slowed lung function decline by 57% across the overall...
Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib...
Boehringer Ingelheim today announced that the FDA's Arthritis Advisory Committee recommended (10-7 vote) to approve Ofev® (nintedanib) for the...
Boehringer Ingelheim today announced results from two pediatric studies of Pradaxa®, which were presented at the International Society on Thrombosis...
Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital...
Boehringer Ingelheim today announced the resolution of all intellectual property-related litigation with AbbVie concerning Cyltezo® (adalimumab-adbm) ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.